
Daewoong pharmaceutical Co.,Ltd
069620.KS
Updated: 24/09/2026, 05:11:23
Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, and international distribution of a diverse range of pharmaceutical products. Its extensive portfolio provides therapeutic solutions across numerous health disciplines, including treatments for central nervous system disorders, endocrine conditions, musculoskeletal ailments, nephrological issues, oncology, cardiovascular diseases, gastrointestinal complaints, and metabolic dysfunctions. The company further offers products addressing viral infections, pain relief, antacids, digestive problems, wound care, and nutritional supplements such as iron and multivitamins. Complementing its pharmaceutical offerings, Daewoong also supplies medical devices, notably COVID-19 PCR and IgG/IgM RDT diagnostic kits, along with viral transport media.
No summaries found.
- Share price
- ₩106,200
- Market cap
- ₩1.22T
- Exchange
- KSC
- Currency
- KRW
- CEO
- Chang-Jae Lee
- Employees
- 1,794
- IPO date
- 29/09/2005
- Beta
- 0.005
- Last dividend
- ₩0
- Day range
- ₩106,000 – ₩109,700
- 52-week range
- ₩105,000 – ₩199,400
- 1-day performance
- -2.39%
- 1-year performance
- 1.14%
- Current drawdown (1Y)
- -46.74%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- KR7069620003
- Created
- 07/09/2026, 05:15:54
- Last update
- 24/09/2026, 05:11:23
Track Daewoong pharmaceutical Co.,Ltd with an AI analyst
See which prediction-market events move 069620.KS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.